Group 1 - China Shenhua plans to issue A-shares and pay cash to acquire assets from its controlling shareholder, China Energy Group, and its wholly-owned subsidiary, West Energy, for a total transaction price of 133.598 billion yuan, with 30% paid in shares and 70% in cash [1][4] - Qingdao Port intends to invest approximately 15.7 billion yuan in two terminal projects [4] - Jifeng Co., Ltd. has been awarded a total assembly project for passenger car seats, with an estimated total lifecycle value of 9.8 billion yuan [4] Group 2 - Shengxin Lithium Energy's partner, Zhongxin Aviation, plans to purchase 200,000 tons of lithium salt products from the company between 2026 and 2030 [4] - Chlor-alkali Chemical's subsidiary plans to invest 2.975 billion yuan in an advanced materials supporting waste salt comprehensive utilization project [4] - Tianqi Lithium's third-phase chemical-grade lithium concentrate expansion project has been completed and is now in trial operation [4] Group 3 - Oriental Cable has recently won projects totaling approximately 3.125 billion yuan [4] - Jiangshan Luneng has signed a series of contracts totaling approximately 815 million yuan [4] - Huahai Wenkang has produced over 800 CMP equipment units [4] Group 4 - Sichuan Chengyu's subsidiary plans to acquire 85% of Jingyi Company for 2.409 billion yuan [4] - Qi Yi Er intends to acquire 60% of Fangzhou Technology through acquisition and capital increase [4] - Tianchuang Fashion is planning a change of control, resulting in a stock suspension [4]

据天眼查APP显示，申联生物医药(上海)股份有限公司成立于2001年06月28日，注册资本41064.4万人民 币。（数据宝） 12月19日申联生物大宗交易一览 | 成交量 | 成交金额 | 成交价 | 相对当日收盘 | | | | --- | --- | --- | --- | --- | --- | | （万 | （万元） | 格 | 折溢价（%） | 买方营业部 | 卖方营业部 | | 股） | | （元） | | | | | | | | | 中信建投证券股份有 | 国信证券股份有限公司上海 | | 205.30 | 1806.64 | 8.80 | -2.33 | 限公司广西分公司 | 陆家嘴环路证券营业部 | （文章来源：证券时报网） 申联生物12月19日大宗交易平台出现一笔成交，成交量205.30万股，成交金额1806.64万元，大宗交易成 交价为8.80元，相对今日收盘价折价2.33%。该笔交易的买方营业部为中信建投证券股份有限公司广西 分公司，卖方营业部为国信证券股份有限公司上海陆家嘴环路证券营业部。 证券时报·数据宝统计显示，申联生物今日收盘价为9.01元，上涨2.15%，日换手率为0.63 ...

Core Viewpoint - The company Shenyuan Biotech (688098.SH) announced that its affiliate Yangzhou Shizhi Source Biotechnology Co., Ltd. has received a patent from the National Intellectual Property Administration for a novel treatment method for HIV infection using monoclonal antibodies targeting CD4 [1] Group 1: Patent and Technology - The patent pertains to a method for treating and functionally curing HIV infection through monoclonal antibodies that target CD4, including their compositions and usage [1] - The drug UB-421, under development by Shizhi Source, has a unique mechanism of action that effectively blocks HIV from entering host cells by competitively binding to the CD4 receptor on T cells [1] Group 2: Market Implications - UB-421 is expected to have a lower probability of inducing viral resistance mutations compared to existing HIV treatments, as it does not directly target viral genes [1] - The drug will primarily focus on areas such as multi-drug resistance and functional cure in the domestic market [1]

Core Viewpoint - The company Shenyuan Biological (688098.SH) announced that its joint venture, Yangzhou Shizhiyuan Biotechnology Co., Ltd. (referred to as "Shizhiyuan"), has recently obtained a patent from the National Intellectual Property Administration for an invention related to the treatment and functional cure of HIV infection using monoclonal antibodies targeting CD4 [1] Group 1 - The patent covers a method for preventing, treating, and functionally curing HIV infection through monoclonal antibodies and their compositions [1] - The drug UB-421, which is in the research pipeline for AIDS treatment, has a novel mechanism of action by competitively inhibiting HIV entry into host cells through binding to the CD4 receptor on T cells [1] - UB-421 is expected to have a lower probability of inducing viral resistance mutations compared to existing AIDS treatments, as it does not directly target viral genes and also possesses immunomodulatory effects [1] Group 2 - The research on UB-421 will primarily focus on areas such as multidrug resistance and functional cure in the domestic market [1]

格隆汇12月19日丨申联生物(688098.SH)公布，公司联营公司扬州世之源生物科技有限责任公司（简 称"世之源"）于近日获得国家知识产权局颁发的"藉由针对CD4之单克隆抗体介导竞争型HIV进入抑制之 HIV感染的治疗和功能性治愈"的发明专利，此发明专利是关于针对CD4单克隆抗体、其组合物以及使 用此组合物以预防、治疗和功能性治愈HIV感染的方法。 本次获得发明专利是公司及世之源重视创新药研发及知识产权布局的成果，为UB-421在多重耐药适应 症的临床推进及开展艾滋病功能性治愈等研究提供了核心技术保护。本次获得发明专利短期内不会对公 司经营业绩产生重大影响，但有利于公司及世之源发挥自主知识产权的技术优势，促进技术创新，进一 步增强公司在创新药领域的布局和核心竞争力。 世之源在研管线艾滋病治疗单克隆抗体药物UB-421具有全新的作用机制，该药物通过与靶向T细胞表面 的CD4受体结构域1结合，以竞争性抑制的方式有效阻断HIV病毒进入宿主细胞。因UB-421并非直接针 对病毒基因，所以相较于当前市场上现有的治疗艾滋病药物，UB-421引起病毒耐药突变的概率较低， 且具有免疫调节作用。UB-421在国内将主要针对多 ...

申联生物医药（上海）股份有限公司 申联生物医药（上海）股份有限公司 简式权益变动报告书 证券代码：688098 证券简称：申联生物 简式权益变动报告书 上市公司：申联生物医药（上海）股份有限公司 股票上市地：上海证券交易所 股票简称：申联生物 股票代码：688098 信息披露义务人 1：上海申太联投资合伙企业（有限合伙） 执行事务合伙人：王锐 注册地址：上海市闵行区江川东路 48 号 1 幢 305 室 信息披露义务人 2：杨玉芳 通讯地址：上海市 信息披露义务人 3：杨从州 通讯地址：上海市 信息披露义务人 4：王东亮 通讯地址：河南省郑州市 申联生物医药（上海）股份有限公司 简式权益变动报告书 信息披露义务人 5：聂东升 通讯地址：上海市 股份权益变动性质：本次权益变动是由于信息披露义务人 1 的执 行事务合伙人变更，导致信息披露义务人 1 与其他信息披露义务人一 致行动关系终止，所持公司股份比例不再合并计算。不涉及各方持有 公司股份数量的变动。 签署日期：2025 年 12 月 19 日 申联生物医药（上海）股份有限公司 简式权益变动报告书 信息披露义务人声明 一、信息披露义务人依据《中华人民共和国证券 ...

本次权益变动系因公司股东之执行事务合伙人发生变更，股东一致行动 关系终止所致，各股东持股数量未发生变化；本次权益变动触及 5%的整数倍， 不触及要约收购； 本次一致行动关系终止不会导致公司控股股东、实际控制人发生变化。 公司于近日收到股东上海申太联投资合伙企业（有限合伙）（以下简称"申 太联"）出具的《关于上海申太联投资合伙企业（有限合伙）执行事务合伙人变 更的告知函》，经申太联全体合伙人一致同意，申太联的执行事务合伙人由上海 亦普商务咨询有限公司（以下简称"亦普咨询"）变更为王锐先生。近日申太联已 完成执行事务合伙人变更（以下简称"本次变更"）的工商登记备案手续，并取得 了上海市闵行区市场监督管理局换发的《营业执照》。 因申太联执行事务合伙人发生变更导致相关一致行动关系终止并触及权益 变动披露义务，公司控股股东、实际控制人聂东升、杨玉芳、杨从州、王东亮及 申太联出具了《关于权益变动的告知函》。本次权益变动后，公司控股股东、实 际控制人聂东升、杨玉芳、杨从州、王东亮持股比例合计由 35.82%相应调整为 30.78%。现将具体情况公告如下： 一、变更情况概述 证券代码：688098 证券简称：申联生物 公告编 ...

申联生物医药（上海）股份有限公司（以下简称"公司"）联营公司扬州 世之源生物科技有限责任公司（以下简称"世之源"）于近日获得国家知识产 权局颁发的"藉由针对CD4之单克隆抗体介导竞争型HIV进入抑制之HIV感染的 治疗和功能性治愈"的发明专利，此发明专利是关于针对CD4单克隆抗体、其 组合物以及使用此组合物以预防、治疗和功能性治愈HIV感染的方法。具体情 况如下： 证券代码：688098 证券简称：申联生物 公告编号：2025-042 申联生物医药（上海）股份有限公司 关于联营公司获得艾滋病单抗发明专利的 自愿性披露公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 2 2 具有免疫调节作用。UB-421在国内将主要针对多重耐药和功能性治愈等领域开 展研究。 本次获得发明专利是公司及世之源重视创新药研发及知识产权布局的成 果，为UB-421在多重耐药适应症的临床推进及开展艾滋病功能性治愈等研究提 供了核心技术保护。本次获得发明专利短期内不会对公司经营业绩产生重大影 响，但有利于公司及世之源发挥自主知识产权的技术优势，促进 ...

Core Viewpoint - The company announced that its joint venture, Yangzhou Shizhiyuan Biotechnology Co., Ltd., has recently been granted a patent by the National Intellectual Property Administration for an invention related to monoclonal antibodies targeting CD4, aimed at preventing, treating, and functionally curing HIV infections [1] Group 1 - The patent is specifically for a method involving monoclonal antibodies against CD4, their compositions, and the use of these compositions in the context of HIV infection [1] - This development represents a significant advancement in the treatment and potential functional cure for HIV, highlighting the company's innovative capabilities in biotechnology [1]

人民财讯12月19日电，申联生物(688098)12月19日公告，联营公司世之源于近日获得国家知识产权局颁 发的"藉由针对CD4之单克隆抗体介导竞争型HIV进入抑制之HIV感染的治疗和功能性治愈"的发明专 利，此发明专利是关于针对CD4单克隆抗体、其组合物以及使用此组合物以预防、治疗和功能性治愈 HIV感染的方法。 ...